Shingrix Vaccine for Shingles
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, it mentions that patients with chronic graft-versus-host disease on stable immunosuppression are eligible, suggesting that some medications may be continued.
Is the Shingrix vaccine generally safe for humans?
The Shingrix vaccine is generally considered safe for humans. In clinical trials, most people experienced mild to moderate reactions like pain at the injection site, muscle pain, and fatigue, which were temporary. Serious side effects were rare and occurred at similar rates as in those who received a placebo.12345
How is the Shingrix vaccine different from other treatments for shingles?
Shingrix is unique because it is a recombinant subunit vaccine, meaning it uses a specific protein from the virus to trigger an immune response, rather than a live virus. It is highly effective, with over 90% efficacy, and is suitable for people aged 50 and older, including those who are immunocompromised, unlike the older live attenuated vaccine.34567
What data supports the effectiveness of the treatment Shingrix for shingles?
Are You a Good Fit for This Trial?
This trial is for adults over 18 who are 1-3 years post-allogeneic stem cell transplant (AlloSCT) for various blood cancers. They must understand and sign consent, not be pregnant, and can have stable chronic graft-versus-host disease. Excluded are those with active primary cancer, acute illness at vaccination time, unsafe thrombocytopenia levels for injections, prior shingles after AlloSCT or allergies to Shingrix vaccine components.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the Shingrix vaccine in standard dosing and schedule
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Shingrix
Shingrix is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Loyola University
Lead Sponsor